SphingoTec CEO to Attend ADLM 2026
During the conference, SphingoTec will engage with current and prospective partners to discuss ongoing collaborations and opportunities to advance innovations in critical care diagnostics. These interactions support SphingoTec's strategy to expand the clinical and commercial reach of its biomarker portfolio.
"ADLM provides an important platform to connect with partners across the diagnostics ecosystem," said
About SphingoTec
SphingoTec GmbH ("SphingoTec"; Hennigsdorf near Berlin, Germany) is a biomarker company focusing on the out-licensing of innovative critical care solutions for diagnosing, predicting, and monitoring acute medical conditions. SphingoTec develops its biomarkers to the commercial stage and partners with IVD companies to make them available on different IVD platforms. SphingoTec's proprietary biomarker portfolio includes Proenkephalin A 119-159 (penKid), a biomarker for the assessment of kidney function in critical diseases, and bioactive Adrenomedullin 1-52 (bio-ADM), a biomarker for the assessment of endothelial function in conditions like sepsis. Discover more on www.sphingotec.com
Media Contact:
Email:[email protected]
Phone +49-3302-20565-0
SphingoTec GmbH
Neuendorfstr. 15A
16761 Hennigsdorf, Germany
Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content:https://www.prnewswire.com/news-releases/sphingotec-ceo-to-attend-adlm-2026-302833290.html
SOURCE SphingoTec GmbH
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- California American Water Advances $2.5 Million Well Rehabilitation Program to Enhance Water System Reliability
- NYU Professor Hong Wang Wins Fields Medal
- Fubo Launches The Athletic’s First CTV Sports Video Hub, Expanding Multi-Year Partnership
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share